S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
The Next Nvidia? (Ad)
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
Did You Get Your Free Bitcoin Yet? (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
The Next Nvidia? (Ad)
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
Did You Get Your Free Bitcoin Yet? (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
The Next Nvidia? (Ad)
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
Did You Get Your Free Bitcoin Yet? (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
The Next Nvidia? (Ad)
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
Did You Get Your Free Bitcoin Yet? (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
Free Trial

Intra-Cellular Therapies (ITCI) Earnings Date, Estimates & Call Transcripts

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)
Free itci Stock Alerts
$72.00
-4.69 (-6.12%)
(As of 04/18/2024 ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Earnings Summary

Upcoming
Earnings Date
May. 2Estimated
Actual EPS
(Feb. 22)
-$0.30 Beat By $0.14
Consensus EPS
(Feb. 22)
-$0.44
Read Call Transcript
Listen to Call
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

ITCI Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ITCI Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Intra-Cellular Therapies Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20241($0.48)($0.48)($0.48)
Q2 20241($0.32)($0.32)($0.32)
Q3 20241($0.01)($0.01)($0.01)
Q4 20241$0.11$0.11$0.11
FY 20244($0.70)($0.70)($0.70)

ITCI Earnings Date and Information

Intra-Cellular Therapies last announced its quarterly earnings data on February 22nd, 2024. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.14. The company had revenue of $132.10 million for the quarter, compared to analysts' expectations of $135.97 million. Its quarterly revenue was up 50.3% compared to the same quarter last year. Intra-Cellular Therapies has generated ($1.46) earnings per share over the last year (($1.46) diluted earnings per share). Earnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($0.69) to $0.79 per share. Intra-Cellular Therapies has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 2nd, 2024 based off prior year's report dates.

Intra-Cellular Therapies Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/2/2024
Estimated)		------- 
2/22/2024Q4 2023($0.44)($0.30)+$0.14($0.30)$135.97 million$132.10 million    
11/2/2023Q3 2023($0.59)($0.25)+$0.34($0.25)$118.35 million$126.17 million
8/3/2023Q2 2023($0.62)($0.45)+$0.17($0.45)$106.45 million$110.80 million    
5/4/2023Q1 2023($0.63)($0.46)+$0.17($0.46)$92.14 million$95.31 million    
3/1/2023Q4 2022($0.62)($0.45)+$0.17($0.45)$86.97 million$87.87 million    
11/3/2022Q3 2022($0.86)($0.57)+$0.29($0.57)$64.95 million$71.87 million
8/9/2022Q2 2022($0.79)($0.92)($0.13)($0.92)$48.62 million$55.58 million    
5/10/2022Q1 2022($0.93)($0.78)+$0.15($0.78)$33.52 million$35.00 million    
3/1/2022Q4 2021($1.05)($1.05)-($1.05)$24.93 million$25.67 million    
11/8/2021Q3 2021($0.92)($0.95)($0.03)($0.95)$22.11 million$22.21 million    
8/8/2021Q2 2021($0.79)($0.85)($0.06)($0.85)$19.04 million$20.00 million    
5/9/2021Q1 2021($0.81)($0.65)+$0.16($0.65)$15.74 million$15.88 million  

Intra-Cellular Therapies Earnings - Frequently Asked Questions

When is Intra-Cellular Therapies's earnings date?

Intra-Cellular Therapies has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 2nd, 2024 based off last year's report dates. Learn more on ITCI's earnings history.

Did Intra-Cellular Therapies beat their earnings estimates last quarter?

In the previous quarter, Intra-Cellular Therapies (NASDAQ:ITCI) reported ($0.30) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.44) by $0.14. Learn more on analysts' earnings estimate vs. ITCI's actual earnings.

How can I listen to Intra-Cellular Therapies's earnings conference call?

The conference call for Intra-Cellular Therapies's latest earnings report can be listened to online. Listen to Conference Call

How can I read Intra-Cellular Therapies's conference call transcript?

The conference call transcript for Intra-Cellular Therapies's latest earnings report can be read online. Read Transcript

How much revenue does Intra-Cellular Therapies generate each year?

Intra-Cellular Therapies (NASDAQ:ITCI) has a recorded annual revenue of $464.37 million.

How much profit does Intra-Cellular Therapies generate each year?

Intra-Cellular Therapies (NASDAQ:ITCI) has a recorded net income of -$139.67 million. ITCI has generated -$1.46 earnings per share over the last four quarters.

What is Intra-Cellular Therapies's EPS forecast for next year?

Intra-Cellular Therapies's earnings are expected to grow from ($0.69) per share to $0.79 per share in the next year.


More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:ITCI) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
[Urgent!] Generational Wealth Gameplan
Crypto 101 Media
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
Biden replacement revealed?
Paradigm Press
The “Perfect Storm” for Gold
Gold Safe Exchange
Did You Get Your Free Bitcoin Yet?
Crypto Swap Profits
Your Money is Not Safe
American Alternative
The Next Nvidia?
InvestorPlace